Wall Street analyst estimates for Quince Therapeutics, Inc. (QNCX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 2 |
| Hold | 5 |
| Sell | 2 |
| Strong Sell | 0 |
| Total analysts | 9 |
| Avg rating (1-5) | 0.00 |
Valuation Ratios
| Price / Book | 1.43 |
| EV / EBITDA | 1.48 |
| Dividend Yield | 0.00% |
Price
| Price | $27.17 |
| Market Cap | $8M |
| Exchange | NASDAQ |
| Country | US |
Explore sector: Healthcare · Biotechnology
More sections of QNCX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks